IASO Biopharma Appoints Dr. Alan Fu as Chief Financial Officer

IASO Bio today announced the official appointment of Dr. Alan Fu (Chong Fu) as Chief Financial Officer, reporting directly to Dr. Wen Wang, CEO of IASO Bio.As a member of the company's senior management team, Dr. Fu Chong will assume overall responsibility for capital market and financial management operations, advancing and deepening the company's sustainable development in capital markets and financial operations.

Dr. Fu is a distinguished leader with dual expertise in scientific research and finance, possessing over 20 years of extensive experience and a proven track record in capital markets, financial management, and scientific research. Prior to joining IASO Bio, Dr. Fu served as Managing Director at Haitong International and Director at Citigroup Global Markets, where he led and facilitated the successful public listings of numerous Chinese enterprises in Hong Kong and the United States, including several in the healthcare sector. Previously, he worked at the Hong Kong office of Davis Polk & Wardwell and the Palo Alto office of Skadden, Arps, Slate, Meagher & Flom, focusing on capital markets transactions, including corporate listings and bond issuances. Earlier in his career, he served as an R&D Scientist at the U.S. biotechnology company Rigel Pharmaceuticals, concentrating on research and drug development in the fields of immunology and oncology.

Dr. Fu earned a Juris Doctor (J.D.) degree from the University of California, Berkeley, a Ph.D. in Molecular Genetics from Washington University in St. Louis, a Master of Science degree in Immunology from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University.

Dr. Fu Chong stated: “IASO Bio is committed to developing innovative cell therapies and antibody drugs aimed at curative outcomes to save the lives of more patients worldwide. This mission holds profound significance for me and fills me with great excitement. The rapid growth of IASO Bio is widely recognized across the industry, particularly this year as several flagship products have achieved outstanding regulatory milestones such as BTD and IND designations, attracting significant attention from the international academic community. I am thrilled to join this dynamic and driven team at such a pivotal juncture in IASO Bio’s expansion. I also hope that my experience in the Hong Kong and U.S. financial markets, along with my understanding of the biopharmaceutical sector, will help the company create even greater value.”

Dr. Wen Wang, Chief Executive Officer of IASO Bio, stated: "Alan is an outstanding leader with dual expertise in biopharmaceutical research and capital market management, possessing a profound understanding of the healthcare system and capital markets. We are delighted to welcome Alan to our leadership team at this pivotal stage as IASO Bio embarks on commercialization and pursues global expansion. His appointment marks a further optimization and strengthening of IASO Bio's executive team. We firmly believe that his professional expertise, leadership, and extensive industry network will accelerate the achievement of the company's key objectives in the next phase!"

# About IASO Bio

IASO Bio is an innovative biopharmaceutical company dedicated to the development and commercialization of cell therapies and antibody drugs. Established in 2017, the company has assembled an international management team with extensive expertise in new drug R&D, clinical research, and commercialization. Anchored by cell-based therapies and antibody drugs for hematologic malignancies as its cornerstone for innovation, IASO Bio is expanding its focus to solid tumors and autoimmune diseases. The company possesses comprehensive end-to-end platform capabilities spanning early discovery, regulatory filing, clinical development, and commercial manufacturing. It also operates multiple specialized technology platforms, including a fully human antibody discovery platform, a high-throughput CAR-T candidate optimization platform, a universal CAR technology platform, a manufacturing technology platform, and a clinical translational research platform. Currently, eight investigational products are at various stages of development. The lead candidate, CT103A (fully human BCMA chimeric antigen receptor autologous T cell injection), has reached late-stage clinical development and was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in February 2021. Furthermore, the Investigational New Drug (IND) applications for two clinical trials of the company’s independently developed innovative product CT120 (fully human CD19/CD22 dual-target CAR-T cell injection) received implied approval from the CDE of the NMPA in July this year, targeting relapsed/refractory CD19/CD22-positive B-cell non-Hodgkin lymphoma (B-NHL) and relapsed/refractory acute B-lymphoblastic leukemia (B-ALL), respectively.

Backed by a management team with strong execution capabilities, a robust product pipeline, and a unique innovative R&D and business model, IASO Bio aspires to become an influential innovative biopharmaceutical company in the industry, advancing innovative therapeutics that genuinely address unmet clinical needs and demonstrate strong market competitiveness from clinical development through to commercialization, thereby paving new therapeutic avenues and bringing new hope to patients. For more details, please visit the company website: www.iasobio.com